Therapeutic Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Dyslipidemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors represent a novel class of medications for managing dyslipidemia. Although previous meta-analyses have confirmed their efficacy in lowering low-density lipoprotein cholesterol (LDL-C), few have evaluated their effects on br...
Spremljeno u:
| Glavni autori: | , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Universitas Padjadjaran
2025-09-01
|
| Serija: | Althea Medical Journal |
| Teme: | |
| Online pristup: | https://journal.fk.unpad.ac.id/index.php/amj/article/view/4209 |
| Oznake: |
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|